Nausea, which is a common early side effect of tirzepatide, may be amplified in people taking certain antidepressants that also cause gastrointestinal upset
These gastrointestinal events were predominantly of minor to intermediate severity
However, there is still a significant difference between the WL that can be achieved with bariatric surgery and the currently approved obesity pharmacotherapies and there is heterogeneity in treatment responses with GLP-1 RA (for example people with T2D may achieve less WL compared to those without diabetes in clinical trials, despite similar lifestyle interventions) [13, 14]
Both medications need medical evaluation, follow-up, and a broader treatment plan, but the candidacy discussion can shift depending on appetite patterns, prior weight regain, obesity-related conditions, and how the provider interprets the full health picture